A single intraperitoneal injection of endotoxin in rats induces long-lasting modifications in behavior and brain protein levels of TNF-α and IL-18

Journal of Neuroinflammation

Laura Petrosini²  Carlo Caltagirone¹  Paola De Bartolo²  Francesca Gelfo¹  Daniela Laricchiuta²  Francesco Angelucci¹  Paola Caporali²  Ilaria Palladino¹  Debora Cutuli²  Paola Bossù¹ 

[1] Clinical and Behavioral Neurology, IRCCS Fondazione Santa Lucia, Via Ardeatina 306, 00179, Rome, Italy;Dipartimento di Psicologia, Università “Sapienza”, Via dei Marsi 78, 00185, Rome, Italy

关键词: Cerebellum;    Frontal cortex;    Hippocampus;    Cytokines;    Behavioral impairment;    Lipopolysaccharide (LPS);    Neuroinflammation;   

Others  :  1212591
DOI  :  10.1186/1742-2094-9-101

 received in 2011-11-11, accepted in 2012-05-29,  发布年份 2012

【 授权许可】

   
2012 Bossù et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Perry VH, Cunningham C, Holmes C: Systemic infections and inflammation affect chronic neurodegeneration. Nat Rev Immunol 2007, 7:161-167.
• [2]Holmes C, Cunningham C, Zotova E, Woolford J, Dean C, Kerr S, Culliford D, Perry VH: Systemic inflammation and disease progression in Alzheimer disease. Neurology 2009, 73:768-774.
• [3]Holmes C, El-Okl M, Williams AL, Cunningham C, Wilcockson D, Perry VH: Systemic infection, interleukin 1beta, and cognitive decline in Alzheimer’s disease. J Neurol Neurosurg Psychiatry 2003, 74:788-789.
• [4]Gao HM, Hong JS: Why neurodegenerative diseases are progressive: uncontrolled inflammation drives disease progression. Trends Immunol 2008, 29:357-365.
• [5]Mrak RE: Neuropathology and the neuroinflammation idea. J Alzh Dis 2009, 18:473-481.
• [6]Gatti S, Bartfai T: Induction of tumor necrosis factor-alpha mRNA in the brain after peripheral endotoxin treatment: comparison with interleukin-1 family and interleukin-6. Brain Res 1993, 624:291-294.
• [7]Laye S, Parnet P, Goujon E, Dantzer R: Peripheral administration of lipopolysaccharide induces the expression of cytokine transcripts in the brain and pituitary of mice. Brain Res Mol Brain Res 1994, 27:157-162.
• [8]Pitossi F, del Rey A, Kabiersch A, Besedovsky H: Induction of cytokine transcripts in the central nervous system and pituitary following peripheral administration of endotoxin to mice. J Neurosci Res 1997, 48:287-298.
• [9]Dantzer R: Cytokine-induced sickness behavior: where do we stand? Brain Behav Immun 2001, 15:7-24.
• [10]Barrientos RM, Higgins EA, Biedenkapp JC, Sprunger DB, Wright-Hardesty KJ, Watkins LR, Rudy JW, Maier SF: Peripheral infection and aging interact to impair hippocampal memory consolidation. Neurobiol Aging 2006, 27:723-732.
• [11]Barrientos RM, Watkins LR, Rudy JW, Maier SF: Characterization of the sickness response in young and aging rats following E. coli infection. Brain Behav Immun 2009, 23:450-454.
• [12]Cunningham C, Campion S, Lunnon K, Murray CL, Woods JF, Deacon RM, Rawlins JN, Perry VH: Systemic inflammation induces acute behavioral and cognitive changes and accelerates neurodegenerative disease. Biol. Psychiatry 2009, 65:304-312.
• [13]Cunningham C, Sanderson DJ: Malaise in the water maze: untangling the effects of LPS and IL-1b on learning and memory. Brain Behav Immun 2008, 22:1117-1127.
• [14]Nguyen MD, D’Aigle T, Gowing G, Julien JP, Rivest S: Exacerbation of motor neuron disease by chronic stimulation of innate immunity in a mouse model of amyotrophic lateral sclerosis. J Neurosci 2004, 24:1340-1349.
• [15]Semmler A, Frisch C, Debeir T, Ramanathan M, Okulla T, Klockgether T, Heneka MT: Long-term cognitive impairment, neuronal loss and reduced cortical cholinergic innervations after recovery from sepsis in a rodent model. Exp Neurol 2007, 204:733-740.
• [16]Qin L, Wu X, Block ML, Liu Y, Breese GR, Hong JS, Knapp DJ, Crews FT: Systemic LPS causes chronic neuroinflammation and progressive neurodegeneration. GLIA 2007, 55:453-462.
• [17]Felderhoff-Mueser U, Schmidt OI, Oberholzer A, Bührer C, Stahel PF: IL-18: a key player in neuroinflammation and neurodegeneration? Trends Neurosci 2005, 28:487-493.
• [18]Bossù P, Ciaramella A, Salani F, Vanni D, Palladino I, Caltagirone C, Scapigliati G: Interleukin-18, from neuroinflammation to Alzheimer’s disease. Curr Pharm Design 2010, 16:4212-4223.
• [19]Alboni S, Cervia D, Sugama S, Conti B: Interleukin 18 in the CNS. J Neuroinflammation 2010, 29:7-9.
• [20]Foti F, Laricchiuta D, Cutuli D, De Bartolo P, Gelfo F, Angelucci F, Petrosini L: Exposure to an enriched environment accelerates recovery from cerebellar lesion. Cerebellum 2011, 10:104-119.
• [21]Glowinski J, Iversen LL: Regional studies of catecholaminesin the rat brain. I. The disposition of [3H]norepinephrine, [3H]dopamine and [3H]dopa in various regions of the brain. J Neurochem 1966, 13:655-669.
• [22]Jacewicz M, Czapski GA, Katkowska I, Strosznajder RP: Systemic administration of lipopolysaccharide impairs glutathione redox state and object recognition in male mice. The effect of PARP-1 inhibitor. Folia Neuropathol 2009, 47:321-328.
• [23]Bluthé RM, Dantzer R, Kelley KW: Effects of interleukin-1 receptor antagonist on the behavioral effects of lipopolysaccharide in rat. Brain Res 1992, 573:318-320.
• [24]Pitychoutis PM, Nakamura K, Tsonis PA, Papadopoulou-Daifoti Z: Neurochemical and behavioral alterations in an inflammatory model of depression: sex differences exposed. Neuroscience 2009, 159:1216-1232.
• [25]Ricceri L: Behavioral patterns under cholinergic control during development: lessons learned from the selective immunotoxin 192 IgG saporin. Neurosci Biobehav Rev 2003, 27:377-384.
• [26]Jenkins TA, Harte MK, Stenson G, Reynolds GP: Neonatal lipopolysaccharide induces pathological changes in parvalbumin immunoreactivity in the hippocampus of the rat. Behav Brain Res 2009, 205:355-359.
• [27]Sy HN, Wu SL, Wang WF, Chen CH, Huang YT, Liou YM, Chiou CS, Pawlak CR, Ho YJ: MPTP-induced dopaminergic degeneration and deficits in object recognition in rats are accompanied by neuroinflammation in the hippocampus. Pharmacol Biochem Behav 2010, 95:158-165.
• [28]Sarter M, Givens B, Bruno JP: The cognitive neuroscience of sustained attention: where top-down meets bottom-up. Brain Res Brain Res Rev 2001, 35:146-160.
• [29]Pepeu G, Giovannini MG: Changes in acetylcholine extracellular levels during cognitive processes. Learn Mem 2004, 11:21-27.
• [30]Graybiel AM: The basal ganglia and cognitive pattern generators. Schizophr Bull 1997, 23:459-469.
• [31]Girault JA, Greengard P: The neurobiology of dopamine signaling. Arch Neurol 2004, 61:641-644.
• [32]Weberpals M, Hermes M, Hermann S, Kummer MP, Terwel D, Semmler A, Berger M, Schäfers M, Heneka MT: NOS2 gene deficiency protects from sepsis-induced long-term cognitive deficits. J Neurosci 2009, 29:14177-14184.
• [33]Block ML, Hong JS: Microglia and inflammation-mediated neurodegeneration: multiple triggers with a common mechanism. Prog Neurobiol 2005, 76:77-98.
• [34]Carvey PM, Chang Q, Lipton JW, Ling Z: Prenatal exposure to the bacteriotoxin lipopolysaccharide leads to long-term losses of dopamine neurons in offspring: a potential, new model of Parkinson’s disease. Front Biosci 2003, Suppl 8:26-37.
• [35]Breder CD, Hazuka C, Ghayur T, Klug C, Huginin M, Yasuda K, Teng M, Saper CB: Regional induction of tumor necrosis factor alpha expression in the mouse brain after systemic lipopolysaccharide administration. Proc Natl Acad Sci USA 1994, 91:11393-11397.
• [36]Kakizaki Y, Watanobe H, Kohsaka A, Suda T: Temporal profiles of interleukin-1beta, interleukin-6, and tumor necrosis factor-alpha in the plasma and hypothalamic paraventricular nucleus after intravenous or intraperitoneal administration of lipopolysaccharide in the rat: estimation by push-pull perfusion. Endocr J 1999, 46:487-496.
• [37]Jander S, Schroeter M, Stoll G: Interleukin-18 expression after focal ischemia of the rat brain: association with the late-stage inflammatory response. J Cereb Blood Flow Metab 2002, 22:62-70.
• [38]Yatsiv I, Morganti-Kossmann MC, Perez D, Dinarello CA, Novick D, Rubinstein M, Otto VI, Rancan M, Kossmann T, Redaelli CA, Trentz O, Shohami E, Stahel PF: Elevated intracranial IL-18 in humans and mice after traumatic brain injury and evidence of neuroprotective effects of IL-18-binding protein after experimental closed head injury. J Cereb Blood Flow Metab 2002, 22:971-978.
• [39]Janelsins MC, Mastrangelo MA, Oddo S, LaFerla FM, Federoff HJ, Bowers WJ: Early correlation of microglial activation with enhanced tumor necrosis factor-alpha and monocyte chemoattractant protein-1 expression specifically within the entorhinal cortex of triple transgenic Alzheimer’s disease mice. J Neuroinflammation 2005, 2:23. BioMed Central Full Text
• [40]Alkam T, Nitta A, Mizoguchi H, Saito K, Seshima M, Itoh A, Yamada K, Nabeshima T: Restraining tumor necrosis factor-alpha by thalidomide prevents the amyloid beta-induced impairment of recognition memory in mice. Behav Brain Res 2008, 189:100-106.
• [41]Giuliani F, Vernay A, Leuba G, Schenk F: Decreased behavioral impairments in an Alzheimer mice model by interfering with TNF-alpha metabolism. Brain Res Bull 2009, 80:302-308.
• [42]Terrando N, Monaco C, Ma D, Foxwell BM, Feldmann M, Maze M: Tumor necrosis factor-alpha triggers a cytokine cascade yielding postoperative cognitive decline. Proc Natl Acad Sci U S A 2010, 107:20518-20522.
• [43]Medeiros R, Figueiredo CP, Pandolfo P, Duarte FS, Prediger RD, Passos GF, Calixto JB: The role of TNF-alpha signaling pathway on COX-2 upregulation and cognitive decline induced by beta-amyloid peptide. Behav Brain Res 2010, 209:165-173.
• [44]Culhane AC, Hall MD, Rothwell NJ, Luheshi GN: Cloning of rat brain interleukin-18 cDNA. Mol Psychiatry 1998, 3:362-366.
• [45]Conti B, Park LC, Calingasan NY, Kim Y, Kim H, Bae Y, Gibson GE, Joh TH: Cultures of astrocytes and microglia express interleukin 18. Brain Res Mol Brain Res 1999, 67:46-52.
• [46]Wheeler RD, Culhane AC, Hall MD, Pickering-Brown S, Rothwell NJ, Luheshi GN: Detection of the interleukin 18 family in rat brain by RTPCR. Brain Res Mol Brain Res 2000, 77:290-293.
• [47]Sugama S, Cho BP, Baker H, Joh TH, Lucero J, Conti B: Neurons of the superior nucleus of the medial habenula and ependymal cells express IL-18 in rat CNS. Brain Res 2002, 958:1-9.
• [48]Prinz M, Hanisch UK: Murine microglial cells produce and respond to interleukin-18. J Neurochem 1999, 72:2215-2218.
• [49]Hedtjärn M, Leverin AL, Eriksson K, Blomgren K, Mallard C, Hagberg H: Interleukin-18 involvement in hypoxic-ischemic brain injury. J Neurosci 2002, 22:5910-5919.
• [50]Sifringer M, Stefovska V, Endesfelder S, Stahel PF, Genz K, Dzietko M, Ikonomidou C, Felderhoff-Mueser U: Activation of caspase-1 dependent interleukins in developmental brain trauma. Neurobiol Dis 2007, 25:614-622.
• [51]Dinarello CA: Interleukin 1 and interleukin 18 as mediators of inflammation and the aging process. Am J Clin Nutr 2006, 83:447S-455S.
• [52]Frayling TM, Rafiq S, Murray A, Hurst AJ, Weedon MN, Henley W, Bandinelli S, Corsi AM, Ferrucci L, Guralnik JM, Wallace RB, Melzer D: An interleukin-18 polymorphism is associated with reduced serum concentrations and better physical functioning in older people. J Gerontol A Biol Sci Med Sci 2007, 62:73-78.
• [53]Rothwell NJ, Luheshi G, Toulmond S: Cytokines and their receptors in the central nervous system: physiology, pharmacology, and pathology. Pharmacol Ther 1996, 69:85-95.
• [54]Schmidt OI, Morganti-Kossmann MC, Heyde CE, Perez D, Yatsiv I, Shohami E, Ertel W, Stahel PF: Tumor necrosis factor-mediated inhibition of interleukin-18 in the brain: a clinical and experimental study in head-injured patients and in a murine model of closed head injury. J Neuroinflammation 2004, 1:13. BioMed Central Full Text
• [55]Puren AJ, Razeghi P, Fantuzzi G, Dinarello CA: Interleukin-18 enhances lipopolysaccharide-induced interferon-gamma production in human whole blood cultures. J Infect Dis 1998, 178:1830-1834.
• [56]Dinarello CA: IL-18: a TH1-inducing, proinflammatory cytokine, and new member of the IL-1 family. J Allergy Clin Immunol 1999, 103:11-24.
• [57]Curran B, O’Connor JJ: The pro-inflammatory cytokine interleukin-18 impairs long-term potentiation and NMDA receptor-mediated transmission in the rat hippocampus in vitro. Neuroscience 2001, 108:83-90.
• [58]Sugama S, Wirz SA, Barr AM, Conti B, Bartfai T, Shibasaki T: Interleukin-18 null mice show diminished microglial activation and reduced dopaminergic neuron loss following acute 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine treatment. Neuroscience 2004, 128:451-458.
• [59]Yaguchi T, Nagata T, Yang D, Nishizaki T: Interleukin-18 regulates motor activity, anxiety and spatial learning without affecting synaptic plasticity. Behav Brain Res 2010, 206:47-51.
• [60]Bossù P, Ciaramella A, Salani F, Bizzoni F, Varsi E, Di Iulio F, Giubilei F, Gianni W, Trequattrini A, Moro ML, Bernardini S, Caltagirone C, Spalletta G: Interleukin-18 produced by peripheral blood cells is increased in Alzheimer’s disease and correlates with cognitive impairment. Brain Behav Immun 2008, 22:487-492.
• [61]Alboni S, Montanari C, Benatti C, Blom JM, Simone ML, Brunello N, Caggia F, Guidotti G, Marcondes MC, Sanchez-Alavez M, Conti B, Tascedda F: Constitutive and LPS-regulated expression of interleukin-18 receptor beta variants in the mouse brain. Brain Behav Immun 2011, 25:483-493.
• [62]Capuron L, Miller AH: Immune system to brain signaling: neuropsychopharmacological implications. Pharmacol Ther 2011, 130:226-238.